Introduction
TI1e occurrence of antibodies to transfused factor VIII (factor VIII inhibitors) remains a major problem in the management of haemophilia A. The percentage of patients confronted with this complication at some time in their life ranges from 3.6 to 25% (1) (2) (3) (4) . Inhibitors only appear in haemophilia A p~tients after exposure to. exogenous . factor VIII and develop mostly in child,en, usually within a limited number of exposure days (generally less than: 50) (1, 3, 4) . Inhibitor development in patients previ-, ously tol~rant to factor vrn is a rare event: in a multicenter study .· condl!cted in the United States, an incidence of new inhibitors of 8per 1,000 patient-years of observati~n was found (1) . , The reason why antifactor. VIII antibodies occur in only some
. ,patient$ with haemophilia A 1s not clear. The formation of mhibitors is not related to the nature of the defect in the :'factor VIII gene (5) , but sibling studies suggest a genetic predis-<,:1;. '-'<C>mespomience to:, Dr. K. P~eilinck, Center for Thrombosis and "'"""'"'aJccn, K. U. Leuven-Campus Gasthuisberg, Herestraat 49, Leuven, Belgium position (6) . That a direct relationship exists between the type of product used and inhibitor formation has not yet been proven (4}.
We report here on a clustering of inhibitors within our population of multitransfused haemophilia A patients; this phenomenon was clearly associated with a specitlc factor VIII preparation.
Patients and Methods

Pa,tieht Population
At the introduction in Belgium in May 1990 of more pure factor VIII preparations to replace the previously used lyophilized heat-treated cryoprecipitate, all haemophilia A patients regularly attending the Leuven Haemophilia Clinic (n 234) were randomly assigned to J·eceive either of two newly introduced products. The study was approved by the Committee of Medical Ethics of this institution, FVli!-P (named factor VIII-CPS-P in The Netherlands) is an intermediate-purity concentrate (specific activity 1.5 IU FVIUJmg protein) produced by controlled-pore silica adsorption, followed by pasteurization ( +60° C for 10 h in solution) (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands) (7); FVHI-SD, a high-purity concentrate (specific activity 200 IU FVHI/mg protein), is produced by ion-exchange chromatography and treated with solvent-detergent (0.3% tri[n-butyl]phosphate 1% polysorbate 80) (Biotransfusion, Lille, France) (8) . For both products cryoprecipitate from Belgian donors was used as starting material (9) . HIV-infected patients (n 6) and patients with an inhibitor known for many years (n = 11) were not included in the study. Brothers living in the same household received the same product. Each treatment group thus consisted of 109 patients. Most patients apply home treatment. Follow-up visits were scheduled after 6 months arid yearly thereafter.
Laboratory Tests
Blood for factor VIII inhibitor assay was collected in polystyrene tubes on one tenth volume of 0.11 molll trisodium citrate. Platelet-poor plasma was· obtained by centrifugation at 2,500 x g for 15 min at room temperature, carefully pipetted off and stored in a plastic tube at -30" C until analysed. · Factor VIII-inhibitor levels were measured according to the B.ethesda method (10) . Residual factor VIII levels were determined in a one stage assay (11) adapted to an automated coagulometer ACI.r810 (IL, Milan, Italy) using severe haemophilia A plasma and a micronised silica aPIT reagent (JL, Milap, Italy),
The 'time course of factor VIII inhibition was studied by measuring residual factor vm at different time intervals in a 1 to 1 mixture of a normal plasma pool and patient plasma as described (12) ; the time required for inactivation of 50% of FVIII activity (half inactivation time, t.t.) was calculated.
To analyse whether the inhibitory activity was linked to IgG or IgM, IgG was ,purified from factor VIII inhibitor plasma on protein A Sepharose. The specificity of anti-factor VHI antibodies was further determined using immunoblots in which affinity-purified antibodies were allowed to react with thrombin-digested human recombinant factor VIII (rFVIII) (13) . Blotting of rFVIII was performed as follows: 500 )lg rFVIII (Baxter, CA) was incubated with 2 U thmmbin (Topostatine, Roche, Brussels) for 30 min at 37" C. Digestion was stopped by addition of D-phenyl~Janyl-L propyl-L-arginine chloromethyl ketone (Calbiochem, La Jolla, CA) to a final concentration of O.Olmmol/1. Five Jlg of thrombin-cleaved rFVIU was applied to a 4 to 15% polyacrylamide gel using the Phast (Pharmacia, Uppsala, Sweden). rFVIH fragments were then transf•ern~d to a 0.2 !J.m nitrocellulose membrane (Machery-Nagel, Duren, Germany) which was incubated with 3% gelatin for 30 min at room temperature. Specific antibodies were purified by immunoaffinity on insolubilized rFVIII and dilutions ranging from 5 j.tg/ml to 0.25 !lg/ml were incubated with the FVUI ·nitrocellulose membranes. The binding of antibodies was detected by addition of biotin-labelled anti-human :Fe)' goat IgG followed by avidin-peroxidase and chloronaphtol. . The number of patients screened for inhibitor is given between brackets. 
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Statistical Evaluation · Incidence rates of inhibitors were calculated as the ratio of the number of inhibitors over the patient-years of observation and. confidence intervals (Cl95) for the incidence rates were calculated under the assumption·· of a Poisson distribution. Fisher's e/(act test was . used whenever appropriate.
Results
]. Clinical Outcome
In August 1991 and September 1991 two patients (LM and EL) presented with haemorrhages.resistant to factor VIII transfusions and in both a factor VIII inhibitor was detected (200 and 90 Bethesda Units [BU], respectively). An inhibitor of 29 BU was detected· in the plasma of a third patient (TA) a few days prior to the . development of clinical symptoms. In October 1991 all haemophilia A patients were invited for systematic inhibitor screening; 62% of the patients belonging to the factor VHI-P group were tested and 56% of those from the factorVIIl-SD group. Two additional subjects with an inhibitor were found (PD: 42 BU and MV: 100 BU); both patients had noticed that transfusions were less effective in contro11ing haemorrhages during the previous weeks. In these five patients the plasma factor VIII level 15 min after infusion of 40 U factor VIII per kg body weight rose . to 1-19 U/dl, corresponding to a recovery of 0-22%. In addition, a sixth patient, the brother of PD, had an inhibitor of 1.8 BU but no clinical signs; recovery in this patient was 31%. The third brother of this sibship had no factor VIII antibody and a normal recovery. The six patients who developed an inhibitor had been allocated to factor VIII-P treatment; five of them had indeed been treated exclusively with factor VUI-P and one patient (LM) ·had received small quantities of factor Vlll-SD in addition to factor VIIIcP. None of the patients randomized to factor VIII-SD treatment developed an inhibitor (p = 0.02 consideripg all, inhibitor patients, n 6 or p ·= 0.03 for clinically important inhibitors, n = 5; Fisher's exact test). The distribution of factor VIII-P by the Belgian Red Cross was stopped in October 1991 and a warning letter with a ~ummary of these observations was published in the December 1991 issue of Acta Clinica Belgica (14) . Factor VIII-P had thus been used for 18 months. Incidence rates of clinically important inhibitors were 31/1,000 patient-years of observation (CI95: 9-71/1,000 patient-years) in the group allocated to factor VIII-P therapy and 0/1,000 patient-years (CI95: 0-2211,000 patient-years) in the group allocated to fac-. tor VIII-SD. The characterization of the two groups of patients and the number whose plasma was screened for inhibitors are shown in Table 1 . About 80% of the patients with severe haemophilia were tested in each grqup. Several patients with mild haemophilia had not received factor VIII transfusions during the observation period.
Characteristics of the patients who developed a high titer inhibitor are shown in Table 2 family history of inhibitor formation. All five subjects had antibodies to hepatitis C, as have more . than 90% of our haemophilia patients. One of the patients (PD) was HbsAg positive and had recurrent bouts of malaria contracted during a prolonged stay in Za"ire; although in this patient no inhibitor test was performed immediately prior to entry in the study nor after 6 months, we found it. justified to include him in the· present analysis since his clinical response to infused factor VIII was unaltered up to 3 to 4 weeks before the inhibitor was detected. In four of the patients bleeding episodes were initially treated with FEIBA (activated prothrombin complex concentrate, Immuno, Brussels), with a satisfactory clinicaf response.
Induction of immune tolerance was attempted in the five patients with a clinically important inhibitor. Treatment consisted of daily transfusions of 30 U factor VIII -SD per kg body weight. No major bleeding episodes occurred after starting this treatment regimen. In all patienis a gradual decline of the inhibitor titer was 9bserved (Fig.l) . In four patients (EL, TA, PD, MV), the inhibitor disappeared after 120, 128, 193 and 223 days respectively, with.an in vivo recovery of infused factor VIII returning to normaL One of these has since undergone uneventful orthopedic surgery.
Inhibitor Characterization
investiJ;at:e whether these antifactor VIII antibodies had properties, they were partially characterized. Factor VIII inactivation times ranged from 19 to 35 mirt (see Thble 3) as corrip~red to less than 8 min when measured with plasma from five haemophilia patients with . stable inhibitors adjusted to comparable levels. These inhibitors can therefore be considered as relatively slow-acting. Specific inhibitory activity of the purified IgG fractions isolated on protein A Sepharose Fanged from 2.4 to 20.4 BU/mg IgG. From this it was calculated that IgG accounted at least 85% of the inhibitory activity. . Anti-factor VIII antibodies were directed towards,epitopes on heavy and light chains in all five patients (see Table 3 ). dilution of the affinity purified IgGs, the reactivity towards kDa fragment was the only one to persist, suggesting that a ....... ""'JV'"Y of the anti-factor VIII antibodies were directed towards factor VIII light chain.
15 months after the introduction In Belgium of two new VIII-concentrates, a ·clustering of factor VIII inhibitors found in the patient group randomly assigned to receive the purity factor VIII-P. All patients . developing an in this series were multitransfused subjects with severe PEN.018.0647 haemophilia A. Although the occurrence of a factor VIII inhibitor is a well-known complication of haemophilia A treatment, most inhibitors develop early (generally within 50 exposure days) (3, 4) after the start of replacement therapy. The occurrence of an inhibitor in multi transfused, tolerant patients is a rare event: in the American Cooperative Study (1) , new clinically important inhibitors were detected in 24 of 1 ,306 patients during a 4-year follow-up period (6.2 per 1,000 patient~years, CI95: 3.9-9.2 per 1,000 patient-years) [calculated from (1)]. In a study with human recombinant factor VIII only 1 of 81 previously multi transfused patients developed an inhibitor (14) . In ,the present study 5 out of the 109 patients assigned to the group J)n factor VIII-P therapy developed a clinically important inhibitor within 18 months of follow-up (31 1,000 patient-years of observation). If only patients with haemophilia are considered, this figure becomes even more striking (5 out of 50; 66 per 1,000 patientyears of observation). No inhibitors were founp during the same time period in the group randomized to FVIII-SD (p 0.03 by Fisher's exact test). Even though not all patients responded to out invitation for inhibitor testing, the chance that clinically important inhibitors would have been missed in the FVIH-SD group is remote, since it is unlikely that patients suffering from clinical complications due to a high tlter inhibitor would not have contacted our H;:~emophllia center, in particular after having been called in for inhibitor screening. Moreover, in the group most at risk for inhibitor. development, the patients with severe haemophilia, the response rate was 80%.
It is important to point out that in our study inhibitors developed exclusively in patients exposed to infused factor VIII for more than 200 days, whereas in the American Cooperative Study (1) 92% of clinically important inhibitors developed within 200 days of exposure to factor VIIL The present data demonstrate the association between the appearance of inhibitors and factor VIII-P infusion in previously multitransfused patients. In further support of this, a national study recently conducted. in The Netherlands after a high incidence of inhibitors was reported, led Dutch investigators to the· same conclusion (16) . Remarkably, the number of exposure days to factor VIII-P before the detection of inhibitor ranged from 98 to 170 days (mean 134) ( Table 2 ) which is longer than what has been reported for previously untreated patients (3, 4) . A bias in detection, e. g. due to infrequent inhibitor testing, is unlikely since 4 of the 5 patients (LM, EL, TA and MV) had a negati,ve inhibitor test after 45, 60, 80 and 110 exposure days to factor vm.p respectively. The relatively late appearance of these inhibitors and the fact that they all were detected within 2 months, suggest that the conditions used for pasteurization could have rendered only some batches of factor VIII-P immunogenic; evidence for this is currently lacking and no batch had been used by all five patients.
In .vitro characterization of the inhibitors showed a rather uniform reactivity: a predominant recognition of the FVIH-light .chain and a relatively slow inhibitory action. Whether this slow inhibitory action is specific for this group of inhibitors or is determined by the point in time during inhibitor development cannot be answered at this moment, since no data are available in the literature.
In an attempt to induce immune tolerance, all five inhibitor patients were treated with daily transfusions of 30 U factor VIII-SD per body weight. This treatment was associated with a gradual decline of inhibitor levels, which was not preceded by an initial rise. It is however presently unclear whether this decrease in inhibitor levels represents an actual induction of immune tolerance or mere catabolism of IgG antibodies.
In conclusion, this study shows for the first time the association between the development of FVIII inhibitors and a specific factor VIII-concentrate and emphasizes the usefulness of evaluating newly introduced concentrates in a prospective, randomized fashion.
